ABSTRACT -Teriparatide, a therapeutic agent for osteoporosis, has been reported to increase the incidences of bone neoplasms such as osteosarcoma when administered subcutaneously to Fischer 344 (F344) rats for a long term, but its non-carcinogenic dose level following 2-year daily administration has not been established. Here we report detailed studies on the carcinogenicity of teriparatide following longterm administration. When teriparatide was administered subcutaneously to male and female SpragueDawley (SD) rats daily for 2 years, the incidence of osteosarcoma was increased at 13.6 μg/kg/day. The non-carcinogenic dose level was 4.5 μg/kg/day for both males and females. The development of osteosarcoma in SD rats depends on the dose level of, and treatment duration with, teriparatide. Responses of the bones to teriparatide were similar between F344 and SD rats in many aspects. These results suggested that the carcinogenic potential of teriparatide in SD rats is essentially the same as in F344 rats.
INTRODUCTION
It has been reported that human parathyroid hormone (1-84) ) and the N-terminal 1-34 amino acid fragment of PTH (PTH (1-34), teriparatide) increase bone mass by enhancing bone formation, which in turn increase bone strength in ovariectomized monkeys (Fox et al., 2007; Sato et al., 2004) and rats . The effects of these hormonal substances is to increase bone mineral density (BMD) and to prevent bone fractures in postmenopausal women with osteoporosis and these properties to increase BMD in steroid-induced osteoporosis patients have already been verified (Neer et al., 2001; Saag et al., 2007) and these substances are used as therapeutic agents for osteoporosis in many countries. In a carcinogenicity study of PTH (1-84) in Fischer 344 (F344) rats with 2-year daily subcutaneous administration, the incidences of bone neoplasms such as osteosarcoma were increased and the non-carcinogenic dose level was 10 μg/kg/day (Jolette et al., 2006) . Also for teriparatide, bone neoplasms including osteosarcoma were observed at all dose levels tested (5, 30 and 75 μg/kg/day) in a carcinogenicity study in F344 rats with 2-year daily subcutaneous administration . The development of bone neoplasms depended on the duration of the treatment and the dose levels of teriparatide . However, the non-carcinogenic dose level of teriparatide has not been established in any carcinogenicity study in rats with a standard treatment duration of 2 years. In addition, 2-year carcinogenicity studies of PTH (1-84) or teriparatide have not been reported in SpragueDawley (SD) rats, which are as commonly used in carciOsteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)) nogenicity studies as F344 rats. In this study, we investigated the carcinogenicity of teriparatide in detail using SD rats.
MATERIALS AND METHODS

Test compound
Chemically-synthesized teriparatide acetate, an active ingredient of TERIBONE TM Inj. 56.5 μg (Asahi Kasei Pharma Corp., Tokyo, Japan) was used. Lyophilized teriparatide acetate was reconstituted with saline in the morning on each day of dosing and administered into the dorsal subcutis of rats in a dose volume of l ml/kg.
Animals
Male and female SD rats were purchased from Charles River Laboratories Japan, Inc. (Kanagawa, Japan). They were housed individually in stainless steel cages and given commercial rodent chows (CRF-1, Oriental Yeast Co., Ltd., Tokyo, Japan) and tap water ad libitum. The animal rooms were maintained at 21-25°C with relative humidity of 40-70%, ventilation of 15-17 times/hr, and 12-hr light/ dark cycle. Based on the body weights, the animals were randomly assigned to the control and treatment groups. The animal experiments were conducted according to the guidance of the institutional animal ethics committees of the testing facilities.
Study designs
Five individual studies were performed. A summary of the study design is illustrated in Fig.1 . Study-1 was a standard 2-year carcinogenicity study of teriparatide using male and female SD rats (main study). Study-2 was a study to verify reproducibility of the results of Study-1. Study-3 was conducted to investigate the relationship between the age of the animals at the initiation of treatment and induction of osteosarcoma. Study-4 was conducted to evaluate whether a shortened treatment period with teriparatide reduces the risk of osteosarcoma or not. Study-5 was a retrospective toxicokinetic study. The animals Fig. 1 . Study design summary. The duration and age of initiation at the onset of treatment injection are illustrated here. The white shading represents the non-treated period; the gray shading represents the treatment period; the black shading represents the necropsy scheduled.
were observed daily for clinical signs (Studies-1 to 5). The dose volume was adjusted weekly for the first 13 weeks of treatment (Studies-1 to 5) and monthly thereafter (Studies-1 to 4) to account for changes in body weight. Histopathological examination was conducted by an experienced pathologist certified by the Japanese Society of Toxicologic Pathology. An independent peer review of the bone proliferative lesions was performed by a consulting pathologist.
Study-1
As the clinical dose regimen of the TERIBONE TM Inj. 56.5 μg is once weekly administration, a group receiving once weekly dosing of the teriparatide acetate, as well as daily dosing groups (total of 3 dose groups) were included in the study. Teriparatide acetate was administered subcutaneously to 55 SD rats/sex/group (5 weeks of age) for 2 years as follows: once daily at the dose levels of 0 (vehicle), 1.5, 4.5 and 13.6 μg/kg as teriparatide in the daily dosed groups; and once weekly at a dose level of 40.7 μg/kg as teriparatide, 3-fold the high dose in the daily dosed groups. Based on the results of 3-month and 12-month repeated dose toxicity studies in SD rats (unpublished data), the high dose level in the daily dose groups was considered to be the maximum tolerated dose. Anti-PTH (1-34) antibody concentrations were determined by ELISA using POD-labeled anti rat IgG antibody (Cappel, MP Biomedicals, Aurora, OH, USA) on Day 1 and during Weeks 13 and 52. On the day of necropsy, all the animals were anesthetized with ether and sacrificed by exsanguination from the abdominal aorta. The bone mineral content (BMC) and BMD of the right femur were measured using a bone mineral measuring system (DCS-600, Aloka Co., Ltd., Tokyo, Japan). The animals that died or were sacrificed moribund during the course of the study were necropsied as soon as possible. A comprehensive collection of soft organs/tissues was made from all animals, together with several bones such as tibia, femur, lumbar vertebra and sternum. In addition, the bones with neoplasm-suspected radiological changes (SOFTEX Corporation, Kanagawa, Japan) were collected. The organs/tissues collected were fixed and preserved in 10% neutral-buffered formalin, with the exception that the ocular structures were fixed in Davidson's fluid. The organs/ tissues were embedded in paraffin, sectioned and stained with hematoxylin and eosin (HE) for light microscopic examination.
Study-2
Teriparatide acetate was administered subcutaneously to 55 male SD rats/group (4-5 weeks of age) at dose levels of 0 (vehicle), 1.5, 4.5 and 13.6 μg/kg as teriparatide, the same dose levels as in the daily dose groups in Study-1, once daily for 2 years. In addition, a non-treated group (55 male SD rats, 4-5 weeks of age) was included in this study. The animals were necropsied in the same manner as in Study-1. HE-stained specimens were prepared in the same manner as in Study-1 from the tibia, femur, lumbar vertebra, sternum and the other bones with neoplasm-suspected radiological changes and the presence/absence of bone neoplasms was determined by light microscopy.
Study-3
In Study-3, 55 male SD rats/group were used. The vehicle (Group A) or teriparatide acetate at a dose level of 13.6 μg/kg as teriparatide (Group B) was administered subcutaneously to the animals from 4 or 5 weeks of age once daily for 18 months. These animals were maintained untreated for 6 months and then necropsied. The vehicle (Group C) or teriparatide acetate at a dose level of 13.6 μg/kg as teriparatide (Group D) was administered subcutaneously to the animals from 30 or 31 weeks of age once daily for 18 months and the animals were necropsied without an untreated period. The presence/absence of bone neoplasms was determined in the same manner as in Study-2.
Study-4
The vehicle or teriparatide acetate at a dose level of 13.6 μg/kg as teriparatide was administered subcutaneously to 55 male SD rats/group (4-5 weeks of age) daily for 6 months and the animals were necropsied following an 18-month untreated period. The presence/absence of bone neoplasms was determined in the same manner as in Study-2.
Study-5
Teriparatide acetate was administered subcutaneously to male and female SD rats (5 weeks of age) at dose levels of 4.5 and 13.6 μg/kg as teriparatide once daily for 13 weeks. Blood samples were collected from 5 animals/ time point at 8 time points on Day 1 and during Week 13. The plasma concentration of teriparatide acetate was quantified using a High Sensitivity Human PTH (1-34) ELISA kit (Immutopics, Inc., San Clemente, CA, USA) according to a previously validated method. Pharmacokinetic parameters were calculated using a standard noncompartmental model (WinNonlin software version 5.2; Pharsight; St. Louis, MO, USA). The anti-PTH (1-34) antibody concentrations were also determined by ELISA using protein A-peroxidase (ZYMED Laboratories, Inc., South San Francisco, CA, USA) and peroxidase substrate kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA) on Day 1 and during Week 13.
Statistical analyses
The statistical significance of the differences between the vehicle control and treatment groups was determined at 5% and 1% probability levels. The survival curve was estimated using the Kaplan and Meier method and the survival rate was analyzed using the Cox-Mantel test. Peto's test or Fisher's exact probability test was conducted for the incidence of each neoplasm depending on whether there were significant differences in the cumulative survival rate between the groups or not. Bartlett's test was conducted to determine the homogeneity of variance (5% level of significance) for the body weights and BMC and BMD of the femur in Study-1 and the body weights in Study-2. Then Dunnett's test or the non-parametric Dunnett's test was conducted depending on whether the variance was homogeneous or heterogeneous. The body weights in Studies-3 and 4 were analyzed for equality of variance using the F-test. Then Student's t-test or AspinWelch's t-test was conducted depending on whether the variance was equal or not.
RESULTS
No toxicity was noted in the clinical signs or body weights in any of Studies-1 to 5. No increases in the anti-PTH (1-34) antibody concentration were noted in Study-1 or 5.
Study-1
Survival curves are presented in Figs. 2 and 3. Increases in the survival rate were noted in males in the 1.5 and 40.7 μg/kg groups, but the relationship with the treatment was unclear. Therefore, these changes were considered not to be the effects of treatment with teriparatide. There were no appreciable differences in the survival rate of females between the vehicle control and teriparatide treated groups. No effects of treatment with teriparatide were noted in the mean survival period (Table 1) . Dose-dependent increases in BMC and BMD of the femur were noted and the increases were marked particularly in the 13.6 μg/kg group (the increased rates of the BMC were 116% in males and 121% in females and those of the BMD were 79% in males and 72% in females, Table 2 ). Thickening of the cortical bone, osteosclerosis and decrease of the bone marrow cavity in the femur were observed in males and females especially in the 13.6 μg/kg group. These findings were considered to be attributable to the osteogenic effect of teriparatide. Extramedullary hematopoiesis in the spleen was also observed in males and females especially in the 13.6 μg/kg group. This change was considered secondary to the decrease of the bone marrow cavity (Table 3) . Fibrous osteodystrophy or other histologic abnormalities suggestive of altered bone quality were not observed.
Osteosarcoma was first detected as neoplasm-suspected radiological changes by X-ray in a male rat that died on day 375 of treatment (58 weeks of age) in the 13.6 μg/kg group. In this animal, osteosarcoma was observed in the cervical and thoracic vertebrae by histopathology. The incidences of bone proliferative lesions and those of osteosarcoma at each bone site are presented in Tables 4 and  5 , respectively. Osteosarcoma was observed in 1 male in the 1.5 μg/kg group and in 9 males and 2 females in the 13.6 μg/kg group. Osteoblastoma was observed in 1 male and 1 female in the 13.6 μg/kg group. A statistically significant increase in the incidence of osteosarcoma was noted in males in the 13.6 μg/kg group as compared to the vehicle control group. Osteosarcoma was observed in the tibia (Figs. 4a and 4b) , femur, cervical vertebra, thoracic vertebra, lumbar vertebra (Figs. 4c and 4d) , rib or scapula. Invasion/metastasis of osteosarcoma to the skeletal muscle, spinal cord, lung, kidney, spleen, adrenal, thymus or pancreas was observed in 6 males in the 13.6 μg/kg group. Osteosarcoma observed in 1 male in the 1.5 μg/kg group was considered to be spontaneous since this lesion was not observed in any male or female in the 4.5 μg/kg group. No statistically significant increases were noted in the incidences of neoplasms other than osteosarcoma in any organ/tissue examined in teriparatide treated group. Based on these results, when teriparatide was administered subcutaneously to SD rats daily for 2 years, the noncarcinogenic and carcinogenic dose levels were judged to be 4.5 and 13.6 μg/kg/day, respectively. No bone neoplasms were observed in the group receiving teriparatide once weekly at 40.7 μg/kg.
Study-2
Survival curves are presented in Fig. 5 . The survival rates in the 4.5 and 13.6 μg/kg groups were statistically significantly decreased as compared to the vehicle control group, but were comparable to the non-treated group. No effects of treatment with teriparatide were noted in the mean survival period (Table 6) . Osteosarcoma was first detected as neoplasm-suspected radiological changes by X-ray in a male rat that died on day 554 of treatment (84 weeks of age) in the 13.6 μg/kg group. In this animal, osteosarcoma was observed in the tibia by histopathology. Osteosarcoma was observed in 9 animals in the 13.6 μg/kg group. Osteosarcoma was observed in the tibia, femur, lumbar vertebra, coxal bone, pubis/ischium, rib or thoracic vertebra (Table 7) . Although osteosarcoma was also observed in the tibia in 1 animal in the 4.5 μg/kg group, this finding was considered to be spontaneous since spontaneous occurrence of osteosarcoma in SD rats has been reported (Imai and Yoshimura, 1988; Mac Kenzie and Garner, 1973; Nagayabu et al., 2000) and osteosarcoma was also observed in 1 animal each in the vehicle control group in Studies-3 and 4. No bone neoplasms other than osteosarcoma were observed in any group. Based on these results, it was reproduced that the non-carcinogenic and carcinogenic dose levels of teriparatide were 4.5 and 13.6 μg/kg/day, respectively, when administered subcutaneously to SD rats daily for 2 years. 
Study-3
No effects of treatment with teriparatide were noted in the survival rate or mean survival period (Table 8) . Osteosarcoma was first detected as neoplasm-suspected radiological changes by X-ray in a male rat that died on day 601 of experiment (90 weeks of age) in Group D. In this animal, osteosarcoma was observed in the tibia by histopathology. Osteosarcoma was observed in 1, 4, 0 and 3 animals in Groups A, B, C and D, respectively (Table 9) . No bone neoplasms other than osteosarcoma were observed in any group. No statistically significant differences were noted in the incidence of osteosarcoma between Groups B and D, indicating that there were no appreciable differences in the incidence of osteosarcoma even though the age of SD rats at the initiation of treatment was different.
Study-4
No effects of treatment with teriparatide were noted in the survival rate or mean survival period (Table 10) .
Osteosarcoma was observed in the humerus in 1 animal in the vehicle control group, but no bone neoplasms were observed in the teriparatide treated group (Table 11) .
Study-5
The plasma concentration of the teriparatide acetate peaked 15 min postdose in both male and female SD rats in all dose groups, and thereafter decreased gradually (Fig. 6) . The area under the plasma concentrationtime curve (AUC) values of teriparatide acetate increased dose-proportionally. There were no marked gender-related differences in pharmacokinetics in any dose groups. The AUC values of teriparatide acetate in Week 13 increased in comparison to those after the initial dosing; however, by 240 min after administration, teriparatide acetate could not be detected in the plasma. The AUC values of teriparatide acetate per week at the non-carcinogenic (4.5 μg/kg/day) and carcinogenic (13.6 μg/kg/day) dose levels in rats were 3.9-to 11.6-fold and 17.8-to 37.1-fold the AUC values of teriparatide acetate in humans receiv- : Number of rats with osteosarcoma associated with a single bone site. c) : Number of rats with osteosarcoma associated with multiple bone sites. 1.5 μg/kg group: Osteosarcoma was observed in 1 male that sacrifi ced moribund on day 667 of treatment. 13.6 μg/kg group: Osteosarcoma was observed in 5 males that died or were sacrifi ced moribund on days 375, 548, 558, 618, and 663 of treatment, respectively, and in 4 males that sacrifi ced after 2-year treatment. Osteosarcoma was observed in 1 female that was sacrifi ced moribund on day 523 of treatment and in 1 female that sacrifi ced after 2-year treatment. *: Signifi cantly different from vehicle control group at P < 0.05. 4.5 μg/kg group: Osteosarcoma was observed in 1 male that sacrifi ced after 2-year treatment. 13.6 μg/kg group: Osteosarcoma was observed in 6 males that died or were sacrifi ced moribund on days 554, 576, 671, 717, 719, and 725 of treatment, respectively, and in 3 males that were sacrifi ced after 2-year treatment. *: Signifi cantly different from vehicle control group at P < 0.05. ing TERIBONE TM Inj. 56.5 μg, respectively (Table 12) .
DISCUSSION
The results of Studies-1 to 4 clearly indicate that the development of osteosarcoma in SD rats depends on the dose level of, and treatment duration with, teriparatide (Table 13 ). Based on the results of Studies-1 and 2, the non-carcinogenic and carcinogenic dose levels of teriparatide were established to be 4.5 and 13.6 μg/kg/day, respectively, when subcutaneously administered to SD rats daily for 2 years. On the other hand, no bone neoplasms were observed in the animals receiving teriparatide at 40.7 μg/kg once weekly for 2 years in Study-1. This was considered to be due to the fact that once-weekly treatment at 40.7 μg/kg did not reach the carcinogen- Group A (Vehicle): Osteosarcoma was observed in 1 male that sacrificed after 2-year treatment. Group B (13.6 μg/kg): Osteosarcoma was observed in 2 males that died or were sacrificed moribund on days 696 and 712 of treatment, respectively, and in 2 males that were sacrificed after 2-year treatment. Group D (13.6 μg/kg): Osteosarcoma was observed in 2 males that died on days 601 and 670 of treatment, respectively, and in 1 male that was sacrificed after 2-year treatment. ic dose of teriparatide (13.6 μg/kg/day × 7 = 95.2 μg/kg/ week) from the view point of the weekly dose level. In Study-3, since the incidence of osteosarcoma was comparable even though the age of animals at the initiation of treatment was different, the risk for the development of osteosarcoma was considered not to be increased in rats when treatment with teriparatide was started early in life. The results of Studies-3 and 4 suggested that longterm treatment with teriparatide is required for the development of osteosarcoma in rats. This is consistent with the conclusion derived from the published literature using F344 rats . Responses of the bones to teriparatide were similar in many ways between F344 and SD rats. The non-carcinogenic dose level of teriparatide has not been established in F344 rats with 2-year daily subcutaneous treatment, but was 5 μg/kg/day with 20-month daily subcutaneous treatment . Therefore, there were probably no large differences in the carcinogenic potential of teriparatide between F344 and SD rats. The non-carcinogenic dose level of PTH (1-84) in F344 rats was 10 μg/kg/ day with 2-year daily subcutaneous treatment (Jolette et al., 2006) . In consideration of the difference in the molecular weights of PTH (1-84) and teriparatide (ca. 9400 Da versus 4100 Da), the carcinogenic potential in rats was considered comparable between these hormonal substances. It has been reported that PTH acts on the PTH1 receptor existing in osteoblastic cells and enhances bone formation through the following processes in the cells: promotion of proliferation of undifferentiated mesenchymal cells, enhancement of osteoblast differentiation from precursors and inhibition of osteoblast apoptosis (Dempster et al., 1993) . It was considered that when teriparatide was administered to rats at a high dose level (13.6 μg/kg/ day) daily for a long term, exaggerated response of the rat skeleton to the bone-formation-enhancing effect of teriparatide on the osteoblastic cells through the receptor continued for a long term and then osteosarcoma was caused. The teriparatide used in our studies was negative in a battery of in vitro and in vivo genotoxicity tests, including the Ames test, Chinese hamster Don D-6 cell chromosomal aberration test, mouse lymphoma L5178Y thymidine kinase locus assay and the in vivo micronucleus test in SD rats (unpublished data). This fact suggests that osteosarcoma was caused by a non-genotoxic Exposure ratios = AUC rat x 7/AUC human ; where AUC rat = rat AUC value measured at Day 1 or week 13, AUC human = 55.14 ng·min/ml in post-menopausal osteoporotic women receiving 56.5 μg of teriparatide. AUC = area under the plasma concentration-time curve. a) : Expressed as the AUC of teriparatide acetate. Vol. 37 No. 3 carcinogenic mechanism of teriparatide and a threshold (margin of safety) is present for the development of osteosarcoma. In Study-5, when teriparatide was administered to SD rats at 4.5 μg/kg/day (the non-carcinogenic dose level in 2-year daily treatment), the weekly systemic exposure levels (AUC) were 3.9-to 11.6-fold the values when TERIBONE TM Inj. 56.5 μg was administered to humans at the clinically recommended dose of 56.5 μg/week. In addition, 2 years, the treatment duration in Study-1, are approximately 80% of the average lifespan of rats, while 72 weeks, the treatment duration of TERIBONE TM Inj. 56.5 μg in clinical use, are only several percent of the average life-span of humans. Therefore, in consideration of the relationship between development of osteosarcoma and the dose level or treatment duration, the possibility for the development of osteosarcoma by teriparatide was considered to be low in humans since the dose level and treatment duration are limited in humans. Moreover, from the fundamental differences in the bone physiology between rats and humans (Dawson, 1925; Dempster et al., 1993; Sato et al., 2002) , the risk for the development of osteosarcoma by teriparatide treatment is probably low in humans.
In conclusion, we identified that osteosarcoma caused by teriparatide in SD rats is dependent on the dose level and treatment duration and the carcinogenic and noncarcinogenic dose levels were 13.6 and 4.5 μg/kg/day, respectively, following 2-year daily subcutaneous treatment. The carcinogenic potential of teriparatide in SD rats is essentially the same as in F344 rats.
